Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.86 |
| ▸ | PTGES | O14684 | 1/20 | 0.86 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 1/20 | 0.86 |
| ▸ | CASP7 | P55210 | 1/20 | 0.86 |
| ▸ | DHODH | Q02127 | 7/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529524 | 0.92 | HSD17B10 (0.94) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL14286200 | 0.92 | HSD17B10 (1.00) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL1901263 | 0.90 | KDM4E (0.72) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL13957864 | 0.90 | HSD17B10 (0.69) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL19475274 | 0.88 | ALDH1A1 (0.71) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL19475331 | 0.87 | ALDH1A1 (0.84) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL8231321 | 0.87 | DHODH (1.00) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL117422 | 0.87 | PTGES (0.84) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL24685853 | 0.86 | ALDH1A1 (0.69) | HSD17B10ALDH1A1HIF1APTGESALOX5 | |
| SCHEMBL17211739 | 0.86 | DHODH (0.74) | HSD17B10ALDH1A1HIF1APTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-3943159-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| WO-2020196327-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | 株式会社ヤクルト本社 | 2020-10-01 | — | — | WO | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| CN-102417479-A | STAT3 small molecular selective inhibitor and preparation method and application thereof | NANJING UNIVERSITY OF TECHNOLOGY | 2012-04-18 | — | — | CN | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102099352-A | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2011-06-15 | — | — | CN | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-0726254-B1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS (JP) | 1998-05-06 | — | — | EP | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
| EP-0726254-A1 | Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | BCKDK, CBR3, NQO2 | HSD17B10 235/4885ALDH1A1 213/4885HIF1A 1215/4885 |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | AR, KLK3, BRDT | HSD17B10 612/4885ALDH1A1 3667/4885HIF1A 4199/4885 |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | HSD17B10 3117/4885ALDH1A1 3308/4885HIF1A 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.